Clinical trials: Early Initial Therapy
Hodgkin Lymphoma
Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma
Prospective, multicenter, Phase II trial designed to assess whether intensification of ABVD (dd-ABVD) is feasible and can improve the outcome of patients with early stage Hodgkin Lymphoma.
- Trial name
- NCT02247869
- Testing
- dose dense ABVD
- Where
- 37 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Metastatic Colorectal Cancer
COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer
Treatment of metastatic colorectal cancer needs chemotherapy in most of the cases. During these last years, many new chemotherapies and targeted therapies have been developed improving significantly the overall survival of…
- Trial name
- NCT01596790
- Testing
- Blood analysis by EPISPOT and Cellsearch
- Where
- France
- Volunteers
- 168 people
- Sponsor
- University Hospital, Montpellier
Adenocarcinoma, Bronchiolo-Alveolar
Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma
To evaluate among patients with untreated advanced ADC-CBA, impact on the disease control rate after 4 months treatment of an early therapeutic permutation with the first month in the absence of stabilization or objective answer.
- Trial name
- NCT00384826
- Testing
- erlotinib, paclitaxel + carboplatine
- Where
- 9 sites in France
- Volunteers
- 133 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Invasive Early Breast Cancer
A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer
The IES study (A5991012) investigated 4742 patients treated for 2 to 3 years with tamoxifen, who either continued the same treatment or switched to Aromasin® for a total treatment period of 5 years.
- Trial name
- NCT01121549
- Testing
- Aromasin
- Where
- 40 sites in Romania
- Volunteers
- 378 people
- Sponsor
- Pfizer
Delusional Disorder, Brief Psychotic Disorder
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone.
- Conditions
- Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
- Trial name
- FEEL-GOOD (NCT07645443)
- Testing
- FEEL GOOD, Treatment as Usual (TAU)
- Where
- 8 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Stephanie Mehl
Psoriatic Arthritis
Initial Treatment With Golimumab in Early PsA
The investigators will perform a 22-week randomized, double-blind, placebo-controlled trial of golimumab + methotrexate (MTX) versus methotrexate alone in methotrexate-naïve patients with Psoriatic Arthritis (PsA).
- Trial name
- NCT01871649
- Testing
- golimumab, methotrexate
- Where
- 2 sites in Netherlands
- Volunteers
- 51 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Multiple Myeloma
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like…
- Trial name
- NCT04634435
- Testing
- BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Unresectable Hepatocellular Carcinoma
Himalaya Early Access Program
To provide early access (i.e., before marketing authorisation) to tremelimumab 300 mg IV administered once on Day 1 of Cycle 1 plus durvalumab 1500 mg IV followed by durvalumab 1500 mg IV Q4W monotherapy in patients with…
- Trial name
- NCT05345678
- Testing
- Durvalumab, Tremelimumab
- Where
- 4 sites in United States
- Sponsor
- AstraZeneca
Psychological Distress, Cancer
Psychological Experience of Discontinuation an Early Phase Treatment by Patients
While there is currently some study on the motivations and experiences of patients integrating early phase clinical trials, to our knowledge, no study has explored the future of patients coming out of these trials.
- Trial name
- VRAIMENT (NCT03905876)
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 182 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Immune Checkpoint Inhibitor-Related Colitis
Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
The goal of this clinical trial is to compare the effectiveness and safety of Vedolizumab with a short course of steroids compared to standard course of steroids for the treatment of immune checkpoint inhibitor colitis (ICI…
- Trial name
- EVITA (NCT06841705)
- Testing
- Vedolizumab 300 MG Injection [Entyvio], Prednisone (and methylprednisolone), Prednisone Taper
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Shilpa Grover, MD, MPH
Musculoskeletal Diseases
Back-on-Track Studying Early Quality Care
This study is a randomized controlled trial conducted at two clinical sites. The purpose of this study is to determine whether patients with musculoskeletal injuries do better by seeing a primary care provider first versus seeing…
- Trial name
- on-Track (NCT02522923)
- Testing
- Physical Therapist, Primary Care Provider
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Temple University
HIV Infections
Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV
The purpose of this study is to see whether taking interleukin-2 (IL-2) and other anti-HIV drugs affects the course of HIV disease in patients with primary HIV infection (the time period that immediately follows infection with…
- Trial name
- NCT00006441
- Testing
- Lamivudine/Zidovudine, Nelfinavir mesylate, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 398 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Threatened Miscarriage, Early Pregnancy Bleeding
Comparison of Dydrogesterone Alone Versus Dydrogesterone Plus HCG in Threatened Miscarriage
This randomized controlled trial aims to compare the efficacy of Dydrogesterone alone versus Dydrogesterone combined with human chorionic gonadotrophin (HCG) in the treatment of threatened miscarriage in first trimester…
- Trial name
- DYD-HCG (NCT07608133)
- Testing
- Dydrogesterone, Human chorionic gonadotrophin (hCG)
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Pakistan Air Force (PAF) Hospital Islamabad
Relapsed or Refractory B-cell Lymphoma
JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B-cell lymphoma
- Trial name
- NCT06045585
- Testing
- infusion of JY231 injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangdong Second Provincial General Hospital
Lymphoma
High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more…
- Trial name
- NCT00003578
- Testing
- CHOP regimen, carmustine, cyclophosphamide
- Where
- 72 sites in Czechia, Denmark and 2 more
- Volunteers
- 500 people
- Sponsor
- Lymphoma Trials Office
Schizophrenia, Schizotypal Disorder
The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis
The OPUS YOUNG (OY) study investigates the efficacy of early intervention service versus treatment as usual (TAU) for adolescents aged 12-17 years with a first-episode psychosis.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Acute and Transient Psychotic Disorder, Unspecified
- Trial name
- OPUS-YOUNG (NCT04916626)
- Testing
- OPUS YOUNG, Treatment as Usual
- Where
- Denmark
- Volunteers
- 284 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Idiopathic Parkinson's Disease
The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease
Levodopa and non-ergot dopaminergic agonists such as pramipexole are both recommended as the first-line symptomatic treatment for early untreated Parkinson's disease (PD), previous clinical trial indicated that initial…
- Trial name
- NCT01470859
- Testing
- pramipexole, Sinemet CR
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huashan Hospital